Why the study?
Does mycophenolate mofetil and low-dose prednisolone improve systemic sclerosis-related pericarditis?
Does mycophenolate mofetil and low-dose prednisolone improve systemic sclerosis-related pericarditis?
Mycophenolate mofetil combined with low-dose prednisolone may be an effective treatment for systemic sclerosis-related pericarditis.
May support mycophenolate mofetil plus low-dose prednisolone for systemic sclerosis pericarditis; leaves open need for controlled trials.
We herein report a case of systemic sclerosis (SSc)-related pericarditis successfully treated with mycophenolate mofetil (MMF) and low-dose prednisolone (PSL). The patient was a 72-year-old woman with anti-centromere antibody. Her clinical manifestations were Raynaud phenomenon, bilateral pleural effusion, pericardial effusion and skin tightness. Based on the findings of exudative pericardial effusion with the absence of pulmonary arterial hypertension from the results of the cardiac catheter and pericardiocentesis, she was diagnosed with SSc-related pericarditis and treated with PSL10 mg and MMF 1 g per day, leading to the complete resolution of pericarditis. These findings suggested that MMF and low-dose PSL were effective for SSc-related pericarditis.
No takes yet. Share an insight, caveat, or question.
Higashioka et al. (2022) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: